Real Kashmir FC's rise as a top side in the I-League has been "nothing short of a fairytale", feels its Scottish coach David Robertson, who is happy to have refused more lucrative assignments in other countries considering the "pure passion" for the beautiful game in the Kashmir Valley.
Stiff competition in a highly fragmented market has led the domestic drug makers to depend on brand extensions rather than new product launches to corner a market share. A market intelligence study, organised by prescription audit company ORG IMS Health, has found that one in every three brands launched in the country is a brand extension. Such products comprise 18 per cent of the Rs 28,000-crore domestic pharmaceutical market.
"A report says that sale of anti-depressant drugs has increased in the last one year," says Samir Parikh, a psychiatrist. More and more people are resorting to the medicine resulting in a noticeable rise in the sale volume, especially in Mumbai, the financial capital, according to experts.
Voveran, Novartis India's flagship pain killer medicine, has become the largest selling domestic drug with sales of more than Rs 11 crore (Rs 110 million) in March 2008, displacing Pfizer India's cough and cold syrup Corex, which had sales of Rs 10 crore (Rs 100 million). Cipla, on the other hand, maintained its leadership position as the largest domestic pharmaceutical company edging out Ranbaxy Laboratories with a market share of 5.24 per cent.
Retail sales of Ranbaxy Laboratories, Cipla, Nicholas Piramal, Lupin and other drug makers have jumped by over 10 per cent in the domestic market despite the sales of generics or copycat versions of patented drugs falling in leading global markets such as the US and Europe.
Foreign multinational drug makers, barring GlaxoSmithKline Pharmaceuticals, continue to have a miniscule presence in the domestic market even after the product patent regime came into being.
Cipla tops pharma rankings with 5.42% market share, ahead of Ranbaxy and GSK.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances